Navigation Links
Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Date:3/17/2011

to treat pre-cancerous cervical dysplasias and cancers caused by human papillomavirus (HPV) types 16 and 18. All dose groups developed significant antibody and T-cell immune responses; notably, in the third and final dose group, five of six (83%) patients developed unprecedented T-cell responses not achieved by any other non-replicating vaccine platform in humans. VGX-3100 delivered using Inovio's proprietary CELLECTRA® intramuscular electroporation delivery device was generally safe and well tolerated at all dose levels. There were no vaccine-related serious adverse events; reported adverse events and injection site reactions were mild to moderate and required no treatment.

Subsequent to year end, Inovio initiated a Phase II clinical trial for VGX-3100. The study will assess adult females with CIN 2/3 or CIN 3, the pre-cancerous stages of abnormal cells that precede cervical cancer, and biopsy-proven HPV 16 or 18, which are responsible for 70% of CIN 2/3 and cervical cancer incidences. The randomized, placebo-controlled, double-blind study will evaluate cervical tissue changes after three 6 mg doses of VGX-3100 are administered by injection in combination with Inovio's CELLECTRA® electroporation delivery device. The company expects that a total of 148 patients will be enrolled in 25 study centers in the U.S., South Korea, South Africa, Australia, and Canada.

During 2010, Inovio observed in an interim analysis high vaccine-induced response rates and strong magnitude of immune responses in its Phase I clinical study of PENNVAX™-B, a DNA vaccine for the prevention of HIV infection.

A Phase I study, called RV262, began to evaluate a unique prime-boost preventive HIV vaccination strategy aimed at global coverage. The prime is Inovio's plasmid DNA vaccine, PENNVAXTM-G. The NIAID, part of the U.S. National Institutes of Health (NIH), is sponsoring th
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
2. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
3. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
4. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
5. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
6. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
7. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
8. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
9. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
10. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
11. Akrimax Pharmaceuticals, LLC, Introduces NitroMist® (Nitroglycerin Lingual Aerosol) 400mcg/Spray
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
(Date:12/24/2014)... Dec. 23, 2014  Advanced Medical Isotope Corporation ... primarily in the development of brachytherapy devices and ... announced that it has filed a de ... Administration ("FDA") for marketing clearance for its patented ... the U.S. Food, Drug and Cosmetic Act (the ...
(Date:12/24/2014)... , Dec. 23, 2014   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... (EMA) of the Marketing Authorization Application (MAA) for ... granted the company,s request for accelerated assessment, which ... review time.   The MAA, and ...
Breaking Medicine Technology:Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... BETHLEHEM, Pa., April 26, 2011 In collaboration ... for Anticancer Drug Research (CESAR) announced today that ... paclitaxel therapeutic drug management (TDM) with subsequent pharmacokinetic-guided ... non-small cell lung cancer (NSCLC).  The study will ...
... International Limited (NYSE: MR ), a leading developer, ... it will report its financial results for the first quarter ... May 9, 2011. Mindray,s management will hold an earnings conference ... Time (8:00 PM on May 10, 2011 Beijing/Hong Kong Time). ...
Cached Medicine Technology:Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer 2Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer 3Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer 4Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer 5Mindray to Report First Quarter 2011 Financial Results on May 9, 2011 2
(Date:12/26/2014)... Los Angeles, CA (PRWEB) December 26, 2014 ... buyer power score of 3.1 out of 5. This ... from a low level of product specialization, low switching ... buyer power is reduced by the low availability of ... in the world price of steel and aluminum, key ...
(Date:12/26/2014)... The Biofeedback Federation of Europe annual ... in Rome, Italy and is hosted by the Salesian ... on a wide variety of topics such as ADHD, ... training in athletes. The scientific program will feature the ... monitoring allows clients to see what is going on ...
(Date:12/26/2014)... 26, 2014 “Many people become overwhelmed ... injury claim issues and phone calls with insurance companies,” ... article featuring their free eBook on pedestrian and ... on pedestrian and bicycle auto accident claims assures the ... capable of professionally handling their case while they focus ...
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on the Best ... 2014. The awards program, created in 2000, is one ... the country. The program is a public/private partnership between ... Economic Development, the Pennsylvania State Council of the Society ... Journal. , Charlie Wilson, Vice President of ...
(Date:12/26/2014)... 26, 2014 Parker & Sons, ... best in heating, cooling and plumbing contractor services ... emergency services in 2014 with regard to air-conditioning ... Arizona is known for its incredibly hot summers. ... the intricacies and details of a wide variety ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3
... UK and US working together explained that they have ... rare, progressive childhood //disorders caused by an abnormal build ... about the discovery of the PLA2G6 gene, whose mutated ... they said that this could also shed light on ...
... have conceived a new way of freezing human eggs which will ... //, to be able to have children. , ,Women’s eggs ... thawed, in contrast to sperms which can be easily frozen and ... by the Japanese researchers which hold promise over the present technique ...
... Director of Fertile Hope has given birth to a baby girl ... // event for Beck who was diagnosed with tongue cancer at ... permanent infertility. ,Facing a void of resources concerning ... educate herself. Upon learning her of her risk of infertility, she ...
... by her biological parents a ... left to drown in an ... But the little infant survived ... a critical heart surgery. ...
... during childbirth to ease the pain during labor. But such ... The National Patient Safety Agency (NPSA) in response has issued ... show that about 200 errors have been committed due a ... to be administered at the base of the spine, but ...
... cancer can talk to doctor through their beloved ones, especially ... ,The head of the Prostate Cancer Foundation, Leslie ... are daughters, wives and partners whom can realize their role ... prostrate cancer. ,More than 27,000 men were ...
Cached Medicine News:Health News:Rare Nerve Disease Causing Gene Identified 2Health News:Cancer Survivor Gives Birth To Baby Girl 2
Lightweight, cordless lensmeter....
Lightweight, cordless lensmeter....
Woodlyn Lensmeter is designed to be used in either a prescription laboratory setting or professional office. Its titable position angle offers personal comfort. The easily operated marking device pro...
Nidek Fundus Camera NM-200D's compact, lightweight body with user-friendly color touch screen display provides more options to treat more patients, and is more comfortable to use....
Medicine Products: